cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.18112/openneuro.ds003216.v3.0.6
title: Acquisition and processing methods of whole-brain layer-fMRI VASO and BOLD: The Kenshu dataset
DOI: 10.2906/099101100101102111112/2
title: Skill needs forecasts: job opportunities

description: Cedefop skill supply and demand forecasts provide comprehensive information on the future labour market trends in Europe. The forecasts act as an early warning mechanism to help to alleviate potential labour market imbalances and support different labour market actors in making informed decisions. Job opportunities represent the sum of net employment change and replacement demand. The concept of replacement demand is based on the fact that some jobs become available due to people leaving work places for different reasons (retirement, migration etc.) These vacant positions need to be filled. In practice the replacement needs are much higher than the net change of employment (expansion demand). As the distribution of those leaving the labour forces is difficult to estimate on the yearly basis, the replacement needs for the period 2013 – 2025 are provided.
DOI: 10.2906/12028373635324/1
title: National Interoperability Framework Observatory (NIFO) – Digital Public Administration factsheets 2020

description: The Digital Public Administration Factsheets provide a comprehensive overview of the most recent digital government developments in 37 European countries and in the European Union. They are published as part of the National Interoperability Framework Observatory (NIFO) project and constitute a vital step in the process of monitoring the development in Digital Public Administration in Europe.
DOI: 10.6084/m9.figshare.21435804
title: GSM3262860_human_sperm_atacseq_THSS.bw

description: <strong>GSM3262860_human_sperm_atacseq_THSS.bw</strong>
DOI: 10.6084/m9.figshare.21435804.v1
title: GSM3262860_human_sperm_atacseq_THSS.bw

description: <strong>GSM3262860_human_sperm_atacseq_THSS.bw</strong>
DOI: 10.6084/m9.figshare.21435921
title: External_Data

description: pLI score
DOI: 10.6084/m9.figshare.21435921.v1
title: External_Data

description: pLI score
DOI: 10.5522/04/19686228.v1
title: Additional material for paper "On the Relationship Between Story Point and Development Effort in Agile Open-Source Software"

description: This record is supplementary to the paper entitled "On the Relationship Between Story Point and Development Effort in Agile Open-Source Software", accepted for presentation at the 16th ACM/IEEE International Symposium on Empirical Software Engineering and Measurement. It contains the R scripts and datasets used in the study, and the online appendix containing additional results. <br>
DOI: 10.5522/04/19686228
title: Additional material for paper "On the Relationship Between Story Point and Development Effort in Agile Open-Source Software"

description: This record is supplementary to the paper entitled "On the Relationship Between Story Point and Development Effort in Agile Open-Source Software", accepted for presentation at the 16th ACM/IEEE International Symposium on Empirical Software Engineering and Measurement. It contains the R scripts and datasets used in the study, and the online appendix containing additional results. <br>
DOI: 10.6084/m9.figshare.21435936
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21435936.v1
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.5522/04/17054273.v2
title: Additional material for the paper "Investigating the Effectiveness of Clustering for Story Point Estimation"

description: This repository contains the data and code used in the paper titled "Investigating the Effectiveness of Clustering for Story Point Estimation" by Vali Tawosi, Afnan Al-Subaihin, and Federica Sarro, accepted at the IEEE International Conference on Software Analysis, Evolution and Reengineering (SANER), 2022.<br>
DOI: 10.5522/04/17054273
title: Additional material for the paper "Investigating the Effectiveness of Clustering for Story Point Estimation"

description: This repository contains the data and code used in the paper titled "Investigating the Effectiveness of Clustering for Story Point Estimation" by Vali Tawosi, Afnan Al-Subaihin, and Federica Sarro, accepted at the IEEE International Conference on Software Analysis, Evolution and Reengineering (SANER), 2022.<br>
DOI: 10.5522/04/17054273.v1
title: Additional material for the paper "Investigating the Effectiveness of Clustering for Story Point Estimation"

description: This repository contains the data and code used in the paper titled "Investigating the Effectiveness of Clustering for Story Point Estimation" by Vali Tawosi, Afnan Al-Subaihin, and Federica Sarro, accepted at the IEEE International Conference on Software Analysis, Evolution and Reengineering (SANER), 2022.<br>
DOI: 10.6084/m9.figshare.21435945
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21435945.v1
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.25934/pr00007372.5
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma'

description: This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.
DOI: 10.5517/ccdc.csd.cc1zz9y6
title: CCDC 1846389: Experimental Crystal Structure Determination

description: Related Article: Gregory R. Lorzing, Eric J. Gosselin, Brian S. Lindner, Rameswar Bhattacharjee, Glenn P. A. Yap, Stavros Caratzoulas, Eric D. Bloch|2019|Chem.Commun.|55|9527|doi:10.1039/C9CC05002G
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc26lwwl
title: CCDC 2043950: Experimental Crystal Structure Determination

description: Related Article: Álvaro Vílchez-Cózar, Eirini Armakola, Maria Gjika, Aurelia Visa, Montse Bazaga-García, Pascual Olivera-Pastor, Duane Choquesillo-Lazarte, David Marrero-López, Aurelio Cabeza, Rosario M. P. Colodrero, Konstantinos D. Demadis|2022|ACS Applied Materials and Interfaces|14|11273|doi:10.1021/acsami.1c21876
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc287y0h
title: CCDC 2092996: Experimental Crystal Structure Determination

description: Related Article: Yanyu Chen, Zhaobo Wang, Wutong Zhao, Shitao Sun, Lu Yang, Junpeng Zhang, Di Zhang, Maosheng Cheng, Bin Lin, Yongxiang Liu|2022|Chem.Commun.|58|3051|doi:10.1039/D1CC07298F
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc296fvt
title: CCDC 2121356: Experimental Crystal Structure Determination

description: Related Article: Álvaro Vílchez-Cózar, Eirini Armakola, Maria Gjika, Aurelia Visa, Montse Bazaga-García, Pascual Olivera-Pastor, Duane Choquesillo-Lazarte, David Marrero-López, Aurelio Cabeza, Rosario M. P. Colodrero, Konstantinos D. Demadis|2022|ACS Applied Materials and Interfaces|14|11273|doi:10.1021/acsami.1c21876
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.21435984
title: FB_Enhancer

description: Fetal Brain Enhancers data
DOI: 10.6084/m9.figshare.21435984.v1
title: FB_Enhancer

description: Fetal Brain Enhancers data
DOI: 10.6084/m9.figshare.21435993
title: ESC_Enhancer

description: ESC enhancers data
DOI: 10.6084/m9.figshare.21435993.v1
title: ESC_Enhancer

description: ESC enhancers data
DOI: 10.6084/m9.figshare.21436005
title: app.R

description: Enhancer Explorer application codes
DOI: 10.6084/m9.figshare.21436005.v1
title: app.R

description: Enhancer Explorer application codes
DOI: 10.5281/zenodo.7266220
title: GiCCS: A German in-Context Conversational Similarity Benchmark

description: We introduce GiCCS, a first conversational STS evaluation benchmark for German. We collected the similarity annotations for GiCCS using best-worst scaling and presenting the target items in context, in order to obtain highly-reliable context-dependent similarity scores. In our paper, we present benchmarking experiments for evaluating LMs on capturing the similarity of utterances. Results<br> suggest that pretraining LMs on conversational data and providing conversational context can be useful for capturing similarity of utterances in dialogues. GiCCS will be publicly available to encourage benchmarking of conversational LMs.
DOI: 10.5281/zenodo.7266256
title: GiCCS: A German in-Context Conversational Similarity Benchmark

description: We introduce GiCCS, a first conversational STS evaluation benchmark for German. We collected the similarity annotations for GiCCS using best-worst scaling and presenting the target items in context, in order to obtain highly-reliable context-dependent similarity scores. In our paper, we present benchmarking experiments for evaluating LMs on capturing the similarity of utterances. Results<br> suggest that pretraining LMs on conversational data and providing conversational context can be useful for capturing similarity of utterances in dialogues. GiCCS will be publicly available to encourage benchmarking of conversational LMs.
DOI: 10.6084/m9.figshare.21436008
title: Supplementary Table S1

description: <strong>Supplementary Table S1:</strong> Statistical significance for absolute and relative changes in risk factor variable from baseline for males and females following RES and END training.
DOI: 10.6084/m9.figshare.21436008.v1
title: Supplementary Table S1

description: <strong>Supplementary Table S1:</strong> Statistical significance for absolute and relative changes in risk factor variable from baseline for males and females following RES and END training.
DOI: 10.5281/zenodo.7267009
title: qrcode data for shift, split and (x,y) coordinates

description: Shift split and (x,y) coordinates corresponding to the qrcode
DOI: 10.5281/zenodo.7267008
title: qrcode data for shift, split and (x,y) coordinates

description: Shift split and (x,y) coordinates corresponding to the qrcode
DOI: 10.6084/m9.figshare.20480787
title: Construction Motion Data Library: An Integrated Motion Dataset for On-Site Activity Recognition

description: Through collecting 16 relatively small-scale motion datasets and conducting a series of in-lab expreiment, we established a 3D skeleton dataset for recognizing construction worker actions. All skeleton data were processed in four major steps, including uniform data extraction, skeleton structure alignment, resampling, and coordination transformation. Then all the aligned skeleton data will be manually annotated into four activity categories and assigned with labels. Experiment version: It contains over 61,275 samples (10 million frames) from 73 classes performed by about 300 different subjects.The dataset includes four fundamental categories of activities, including Production Activities(12), Unsafe Activities(38), Awkward Activities(10), and Common Activities(13). However, We have carefully reviewed the licenses of all the current datasets. We found more than half of the datasets did not specify their licenses and usage policy. Therefore, in this version, we only shared the tagged and processed dataset that clearly allows redistribution and modification. For the rest of the datasets, we highlighted their URL and doi (all of them are publicly accessible and free for use). Instead of providing the processed data, we public the full preprocess codes on GitHub, which could be used to retag and process (such as converting to predefined .bvh files). All readers and users could process the source dataset by themselves. Public version： Construction Motion Data Library(CML) contains 6131 samples(ALL_DATA); among them, and 4333 samples are highly related to construction activities ( Construction_Related_Data). GitHub: https://github.com/YUANYUAN2222/Integrated-public-3D-skeleton-form-CML-library.
DOI: 10.6084/m9.figshare.20480787.v2
title: Construction Motion Data Library: An Integrated Motion Dataset for On-Site Activity Recognition

description: Through collecting 16 relatively small-scale motion datasets and conducting a series of in-lab expreiment, we established a 3D skeleton dataset for recognizing construction worker actions. All skeleton data were processed in four major steps, including uniform data extraction, skeleton structure alignment, resampling, and coordination transformation. Then all the aligned skeleton data will be manually annotated into four activity categories and assigned with labels. Experiment version: It contains over 61,275 samples (10 million frames) from 73 classes performed by about 300 different subjects.The dataset includes four fundamental categories of activities, including Production Activities(12), Unsafe Activities(38), Awkward Activities(10), and Common Activities(13). However, We have carefully reviewed the licenses of all the current datasets. We found more than half of the datasets did not specify their licenses and usage policy. Therefore, in this version, we only shared the tagged and processed dataset that clearly allows redistribution and modification. For the rest of the datasets, we highlighted their URL and doi (all of them are publicly accessible and free for use). Instead of providing the processed data, we public the full preprocess codes on GitHub, which could be used to retag and process (such as converting to predefined .bvh files). All readers and users could process the source dataset by themselves. Public version： Construction Motion Data Library(CML) contains 6131 samples(ALL_DATA); among them, and 4333 samples are highly related to construction activities ( Construction_Related_Data). GitHub: https://github.com/YUANYUAN2222/Integrated-public-3D-skeleton-form-CML-library.
DOI: 10.5281/zenodo.7266982
title: Photo-induced cascaded harmonic and comb generation in silicon nitride microresonators

description: The data and code used to produce the results in the paper "Photo-induced cascaded harmonic and comb generation in silicon nitride microresonators".
DOI: 10.5281/zenodo.7266981
title: Photo-induced cascaded harmonic and comb generation in silicon nitride microresonators

description: The data and code used to produce the results in the paper "Photo-induced cascaded harmonic and comb generation in silicon nitride microresonators".